AB Science SA has announced that its masitinib in sickle cell disease is among the 19 projects to be funded under the “Hospital-University Research in Health” program. This program, part of the Future Investments Program, will support a phase 2 clinical trial for masitinib in sickle cell disease. The initiative, known as the SICKMAST project, aims to identify biomarkers associated with mast cells and basophils, conducting a phase 2 trial to assess masitinib’s efficacy in treating complications. The clinical development is crucial, given the medical need to address acute and chronic complications in sickle cell disease, where existing treatments fall short.

The “Hospital-University Research in Health” (RHU) program, operated by the National Research Agency, supports innovative and large-scale health research projects. In this round, 19 projects were selected for funding out of 62 applications, receiving an exceptional grant of 160 million euros from the Future Investments Program. AB Science’s masitinib project, receiving 9.2 million euros, holds promise for advancing treatment options in sickle cell disease. The company, collaborating with the Assistance Publique-Hôpitaux de Paris (AP-HP), aims to explore the potential of masitinib in targeting key immune cells involved in the complications of sickle cell disease.

This collaboration emphasizes the significance of translational research, converting basic research into direct benefits for patients. The webcast scheduled for November 30, 2023, will provide further insights into the masitinib project and its potential impact on sickle cell disease treatment. The comprehensive approach, including biomarker identification and a phase 2 clinical trial, underscores the commitment to advancing innovative solutions and addressing the complex challenges associated with sickle cell disease, a condition with substantial global impact.

Read more: https://www.globenewswire.com/news-release/2023/11/27/2785856/0/en/AB-Science-The-clinical-development-of-masitinib-in-sickle-cell-disease-is-among-the-19-winning-projects-under-the-sixth-call-for-Hospital-Inuversity-Research-in-health-RHU.html

#sicklecell #masitinib #healthresearch #innovation #clinicaltrial #biomarkers #medicalneed #translationalresearch #futureinvestments #ABScience